Effect of Belimumab on Antibody Titers in Primary APS Patients
NCT06747312
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Antiphospholipid Syndrome (APS)
Interventions
DRUG:
Belimumab+SOC
DRUG:
SOC
Sponsor
Ruijin Hospital